---
canonical_name: Jiaogulan
alternate_names: Gynostemma pentaphyllum, Gynostemma, Southern Ginseng, Five-Leaf Ginseng, Miracle Grass, Immortality Herb, Sweet Tea Vine, Xiancao, Gypenosides, Actiponin, ActivAMP
canonical_topic: Jiaogulan for Health & Longevity
short_topic_lc: jiaogulan
creation_date: 2026-1018-0029
creator_ai_fullname: Gemini 4 Argon
---

# Jiaogulan for Health & Longevity  
<section id="top" markdown="1"></section>  
Evidence Review created on 10/18/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Gemini 4 Argon  

**Also known as:** Gynostemma pentaphyllum, Gynostemma, Southern Ginseng, Five-Leaf Ginseng, Miracle Grass, Immortality Herb, Sweet Tea Vine, Xiancao, Gypenosides, Actiponin, ActivAMP  

  
## Motivation  

<!-- This Motivation section was written last, only after the rest of the document was completed, to ensure it accurately reflects the full scope of the evidence review. -->  

Jiaogulan (*Gynostemma pentaphyllum*, also known as southern ginseng) is a climbing vine native to mountainous regions of East and Southeast Asia. Its leaves contain plant compounds structurally similar to those in true ginseng and trigger the body's main cellular energy-sensing enzyme, mimicking aspects of calorie restriction and physical exercise. Because of this cellular energy-sensing mechanism, longevity-focused adults have explored oral leaf infusions and concentrated extracts for metabolic health, body composition, and physical endurance.  

Historically consumed as a daily mountain tea in southern China and northern Vietnam, the plant drew scientific interest after regional longevity surveys noted widespread use among long-lived rural populations. Researchers subsequently isolated its active plant compounds and initiated human studies examining whether whole-leaf teas or heat-processed leaf extracts influence blood sugar regulation, abdominal fat distribution, blood lipid profiles, and exercise capacity.  

This review examines the clinical, mechanistic, and safety evidence surrounding oral Jiaogulan tea and standardized leaf extracts for health optimization and longevity. It evaluates where human trials support or conflict with laboratory findings, compares traditional infusions with concentrated extracts, and details practical dosing, drug interactions, and laboratory monitoring considerations.  

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**  

  
## Recommended Reading  

<!-- A real-time search for Jiaogulan and Gynostemma pentaphyllum was conducted across priority expert platforms (Rhonda Patrick / foundmyfitness.com, Peter Attia / peterattiamd.com, Andrew Huberman / hubermanlab.com, Chris Kresser / chriskresser.com, Life Extension Magazine / lifeextension.com, and Lifespan.io / lifespan.io) using both web search and direct on-site search, alongside PubMed searches for high-level narrative reviews and landmark primary trials. Life Extension Magazine had directly relevant coverage; the other five priority experts had no coverage. Four qualifying peer-reviewed narrative reviews and landmark primary clinical trials from distinct sources were selected to complete the list. -->  

This section highlights five accessible expert overviews, comprehensive narrative reviews, and landmark primary clinical trials that examine the pharmacology, metabolic mechanisms, and human outcomes of *Gynostemma pentaphyllum*.  

* [Cancer-Fighting Properties of Gynostemma](https://www.lifeextension.com/magazine/2022/10/gynostemma-anti-cancer-properties) - Tim Chasen  

  Summarizes over 230 bioactive compounds in *Gynostemma pentaphyllum*, detailing preclinical tumor suppression, immune modulation, and early human oncology observations from a longevity perspective.  

* [Progress in the Medicinal Value, Bioactive Compounds, and Pharmacological Activities of Gynostemma pentaphyllum](https://pubmed.ncbi.nlm.nih.gov/34684830/) - Su et al., 2021  

  Provides a broad phytochemical and pharmacological overview of gypenosides (triterpenoid saponins unique to Jiaogulan), polysaccharides, and flavonoids across metabolic, hepatic, cardiovascular, and neuroprotective pathways.  

* [Saponins derived from Gynostemma pentaphyllum regulate triglyceride and cholesterol metabolism and the mechanisms: A review](https://pubmed.ncbi.nlm.nih.gov/37722515/) - Xie et al., 2024  

  Maps how 328 identified *Gynostemma* saponins regulate lipid and glucose homeostasis through AMPK (adenosine monophosphate-activated protein kinase, a master cellular energy sensor) and hepatic cholesterol pathways.  

* [The effect of an orally-dosed Gynostemma pentaphyllum extract (ActivAMP®) on body composition in overweight, adult men and women: A double-blind, randomised, placebo-controlled study](https://pubmed.ncbi.nlm.nih.gov/34323337/) - Rao et al., 2022  

  Demonstrates in a 16-week RCT (randomized controlled trial, a study randomly assigning participants to an intervention or comparison group) that heat-processed extract reduces fat mass and sex-specific regional adiposity.  

* [Antidiabetic effect of Gynostemma pentaphyllum tea in randomly assigned type 2 diabetic patients](https://pubmed.ncbi.nlm.nih.gov/20213586/) - Huyen et al., 2010  

  Establishes in a 12-week double-blind clinical trial that daily *Gynostemma pentaphyllum* leaf tea lowers fasting plasma glucose, glycated hemoglobin, and insulin resistance without inducing hypoglycemia (abnormally low blood sugar).  

Direct web and on-site searches of Rhonda Patrick (foundmyfitness.com), Peter Attia (peterattiamd.com), Andrew Huberman (hubermanlab.com), Chris Kresser (chriskresser.com), and Lifespan.io (lifespan.io) returned no articles or podcast episodes discussing Jiaogulan or *Gynostemma pentaphyllum*, as Western longevity media has focused primarily on pharmacological AMPK activators such as metformin and berberine.  

  
## Grokipedia  

<!-- Direct searches of grokipedia.com were performed using Section 5 retrieval tiers in order: d-browser navigated to https://grokipedia.com/page/Jiaogulan (returned "Article Not Found — Grokipedia") and then https://grokipedia.com/page/Gynostemma_pentaphyllum, which loaded the genuine primary dedicated article ("Gynostemma pentaphyllum — Grokipedia"); d-fetch also retrieved the same page. -->  

[Gynostemma pentaphyllum](https://grokipedia.com/page/Gynostemma_pentaphyllum)  

Provides a comprehensive reference monograph covering the botanical taxonomy, over 180 dammarane-type gypenosides, traditional East Asian tonic uses, metabolic signaling pathways, and human clinical trial evidence for *Gynostemma pentaphyllum*.  

  
## Examine  

<!-- Direct searches of examine.com for "jiaogulan" and https://examine.com/supplements/jiaogulan/ were performed using Section 5 retrieval tiers in order: d-browser returned a "Vercel Security Checkpoint" interstitial; d-fetch returned HTTP status code 429; d-proxy-1 (browser_navigate) bypassed the bot wall and loaded the genuine primary dedicated page at https://examine.com/supplements/jiaogulan/; d-proxy-2 (scrape_as_markdown) also retrieved the full search results and supplement page. -->  

[Jiaogulan](https://examine.com/supplements/jiaogulan/)  

Synthesizes human clinical trial data on *Gynostemma pentaphyllum* tea and standardized extracts, evaluating its effects on glycemic control, abdominal adiposity, stress-related anxiety, and endurance exercise performance.  

  
## ConsumerLab  

<!-- Direct searches of consumerlab.com for "jiaogulan" and "Gynostemma pentaphyllum" were performed using Section 5 retrieval tiers in order: d-browser navigated to https://www.consumerlab.com/search?q=jiaogulan and https://www.consumerlab.com/answers/does-gynostemma-pentaphyllum-really-work-as-an-ampk-activator-and-help-for-diabetes/gynostemma-pentaphyllum-ampk/, loading both genuine pages without a paywall; d-fetch also retrieved both pages in full. -->  

[Does Gynostemma pentaphyllum really work as an AMPK activator and help for diabetes, high cholesterol, or weight loss?](https://www.consumerlab.com/answers/does-gynostemma-pentaphyllum-really-work-as-an-ampk-activator-and-help-for-diabetes/gynostemma-pentaphyllum-ampk/)  

Evaluates the clinical evidence for *Gynostemma pentaphyllum* teas and damulin-standardized extracts across diabetes, weight loss, cholesterol, and hair growth, while highlighting hematological and anticoagulant safety precautions.  

  
## Systematic Reviews  

This section summarizes five PubMed-indexed systematic reviews and meta-analyses evaluating *Gynostemma pentaphyllum* across glycemic control, dyslipidemia (abnormal blood lipid levels), stress hormone modulation, and fatty liver disease; while two reviews evaluate adverse events and comparative efficacy against standard therapies, no standalone systematic review exclusively dedicated to Jiaogulan's risks exists.  

* [Efficacy and mechanisms of Gynostemma pentaphyllum as a medicine food homology herb in glycemic control: a meta-analysis with review](https://pubmed.ncbi.nlm.nih.gov/42064816/) - Wang et al., 2026  

  Meta-analysis of eight clinical studies showing significant reductions in fasting glucose, postprandial glucose, and HbA1c (glycated hemoglobin, a three-month blood sugar marker).  

* [The Role of Gynostemma pentaphyllum in Regulating Hyperlipidemia](https://pubmed.ncbi.nlm.nih.gov/37129524/) - Li et al., 2023  

  Meta-analysis of 15 studies demonstrating that *Gynostemma pentaphyllum* lowers serum triglycerides and raises HDL-C (high-density lipoprotein cholesterol, protective cholesterol particles).  

* [Gynostemma pentaphyllum for dyslipidemia: A systematic review of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/36091752/) - Dai et al., 2022  

  Evaluates 22 RCTs, showing superior lipid reductions with lipid-lowering drugs and fewer adverse events, but inferior monotherapy efficacy versus red yeast rice.  

* [Modulation of the hypothalamic-pituitary-adrenal (HPA) axis by plants and phytonutrients: a systematic review of human trials](https://pubmed.ncbi.nlm.nih.gov/33650944/) - Lopresti et al., 2022  

  Reviews 52 human RCTs of botanicals including Jiaogulan on HPA (hypothalamic-pituitary-adrenal, the neuroendocrine stress system) hormones, finding inconclusive cortisol changes.  

* [Herbal medicines for fatty liver diseases](https://pubmed.ncbi.nlm.nih.gov/23975682/) - Liu et al., 2013  

  Cochrane systematic review of 77 RCTs evaluating herbal interventions including *Gynostemma pentaphyllum* for fatty liver disease, noting improved hepatic enzymes without severe toxicity.  

  
## Mechanism of Action  

*Gynostemma pentaphyllum* acts primarily through over 200 dammarane-type triterpenoid saponins called gypenosides (including damulins A and B, gypenoside L, and gypenoside XVII), alongside polysaccharides and flavonoids. Damulins A and B stimulate Thr172 phosphorylation of AMPK, mimicking cellular energy depletion to increase GLUT4 (glucose transporter type 4, an insulin-regulated glucose channel) translocation, fatty acid beta-oxidation, and PGC-1α (peroxisome proliferator-activated receptor-gamma coactivator 1-alpha, a mitochondrial biogenesis regulator). Downstream, gypenosides activate SIRT1 (sirtuin 1, a cellular repair deacetylase) and FOXO1 (forkhead box protein O1, a stress-resistance transcription factor), stimulate eNOS (endothelial nitric oxide synthase, a vasodilatory nitric-oxide enzyme), and inhibit NF-κB (nuclear factor kappa B, an inflammatory transcription complex) and NLRP3 (NOD-like receptor family pyrin domain-containing 3, an inflammasome complex). In the liver, gypenosides suppress SREBP-1c (sterol regulatory element-binding protein 1c, a lipogenic regulator) and PCSK9 (proprotein convertase subtilisin/kexin type 9, a cholesterol-receptor degrader) while activating FXR (farnesoid X receptor, a bile-acid nuclear receptor).  

A competing mechanistic view notes that intact gypenosides have low oral bioavailability (~1.87% in rats, peaking at 0.17–0.20 hours with a 1.94–2.56 hour elimination half-life; human half-life is unestablished), attributing systemic benefits largely to gut-microbiota remodeling and deglycosylation into secondary aglycones. Absorbed aglycones concentrate in hepatic and intestinal tissues, undergo glucuronidation via UGT1A4 (uridine 5'-diphospho-glucuronosyltransferase 1A4, a hepatic conjugation enzyme), and inhibit human CYP2D6 (cytochrome P450 2D6, a drug-metabolizing enzyme) plus CYP2C8, CYP3A4, and CYP2C9 (hepatic cytochrome P450 enzymes) in vitro.  

  
## Historical Context & Evolution  

*Gynostemma pentaphyllum* was first recorded in 1406 CE by Ming Dynasty scholar Zhu Xiao in the *Jiuhuang Bencao* (*Materia Medica for Famine*) as a wild edible survival plant rather than a medicinal tonic. In 1578, Li Shizhen's *Bencao Gangmu* (*Compendium of Materia Medica*) documented regional southern Chinese folk use for hematuria (blood in the urine), edema (fluid retention and swelling), pharyngitis (throat inflammation), and trauma, though historical texts occasionally conflated it with the morphologically similar vine *Cayratia japonica*. Across the mountainous provinces of Guizhou, Guangxi, and Sichuan, rural inhabitants brewed its sweet leaves as a daily tea to relieve fatigue and promote longevity, naming it *Xiancao* ("immortality herb").  

Modern scientific investigation began in the 1970s. Japanese phytochemists Masahiro Nagai and Tsunematsu Takemoto, analyzing the vine as a natural sweetener, isolated dammarane-type saponins chemically identical to panaxadiol and ginsenosides from *Panax ginseng*, establishing *Gynostemma pentaphyllum* as the first non-*Araliaceae* plant known to synthesize ginsenoside-class triterpenoids. Concurrently, Chinese census surveys of centenarian clusters in southern mountain provinces linked routine Jiaogulan tea intake to low rates of metabolic and vascular disease. Clinical studies in the 1990s and 2000s tested whole-leaf teas and total gypenosides for dyslipidemia and type 2 diabetes, while 2010s–2020s research shifted toward heat-processed damulin-enriched extracts for visceral adiposity and endurance performance.  

  
## Expected Benefits  

<!-- A dedicated search for the complete benefit profile of Jiaogulan (Gynostemma pentaphyllum) and gypenosides was conducted across PubMed, ClinicalTrials.gov, Examine.com, and ConsumerLab.com before writing this section. The search specifically included identifying randomized trials and systematic reviews that found no effect, inferior efficacy, or the opposite effect (such as null lipid changes in Park et al. 2014 and Huyen et al. 2010, HDL-C reductions in Jeenduang et al. 2017, null body weight changes in lean diabetics in Huyen et al. 2010, and terminated/null primary optic neuritis outcomes in Lu et al. 2026). -->  

### High 🟩 🟩 🟩  

#### Glycemic Control and Insulin Sensitivity ⚠️ Conflicted  

*Gynostemma pentaphyllum* stimulates AMPK-mediated GLUT4 glucose uptake and inhibits hepatic gluconeogenesis (liver glucose production). A [meta-analysis](https://pubmed.ncbi.nlm.nih.gov/42064816/) by Wang et al. and trials by Huyen et al. ([2010](https://pubmed.ncbi.nlm.nih.gov/20213586/), [2012](https://pubmed.ncbi.nlm.nih.gov/23125867/), [2013](https://pubmed.ncbi.nlm.nih.gov/23431428/)), Chou et al. ([2006](https://pubmed.ncbi.nlm.nih.gov/16708768/)), and Nayyar et al. ([2023](https://pubmed.ncbi.nlm.nih.gov/38004115/)) lowered fasting glucose, HbA1c, and HOMA-IR (homeostatic model assessment for insulin resistance), whereas normoglycemic trials ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/); [Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)) found unchanged fasting glucose. Glycemic reductions are substantial in hyperglycemic patients but minimal in normoglycemic adults.  

**Magnitude:** Across 8 clinical studies (N = 584), fasting plasma glucose decreased by MD (mean difference, the pooled average difference between groups) -0.79 mmol/L (95% CI [confidence interval, the range within which the true effect likely falls] -1.08 to -0.51), HbA1c by MD -1.01% (95% CI -1.41 to -0.61), and 2-hour postprandial glucose by MD -0.90 mmol/L (95% CI -1.95 to -0.15) ([Wang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42064816/)).  

#### Body Weight and Visceral Fat Reduction ⚠️ Conflicted  

Heat-processed damulin extracts stimulate AMPK-driven fat oxidation and inhibit adipogenesis (fat cell formation). Independent RCTs by Park et al. ([2014](https://pubmed.ncbi.nlm.nih.gov/23804546/); [2020 erratum](https://pubmed.ncbi.nlm.nih.gov/32841525/), funded by TG Biotech), Rao et al. ([2022](https://pubmed.ncbi.nlm.nih.gov/34323337/), funded by Gencor Pacific), and Chou et al. ([2006](https://pubmed.ncbi.nlm.nih.gov/16708768/)) reduced weight, BMI (body mass index, weight-to-height ratio), total fat, and visceral fat, whereas leaf tea trials in non-obese diabetics ([Huyen et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20213586/), [2013](https://pubmed.ncbi.nlm.nih.gov/23431428/)) found unchanged weight. Concentrated damulin extracts modestly reduce fat mass in overweight adults, whereas crude tea does not alter weight.  

**Magnitude:** Over 12 weeks (N = 80), 450 mg/day extract reduced total abdominal fat area by -20.90 cm² versus -2.87 cm² with placebo (p = 0.044) and body weight by -1.35 kg versus 0.00 kg with placebo (p < 0.05) ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/); [2020 erratum](https://pubmed.ncbi.nlm.nih.gov/32841525/)); over 16 weeks (N = 117), 450 mg/day reduced weight and fat mass by ~0.9 kg and BMI by -0.24 kg/m² versus placebo ([Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)).  

#### Endurance Exercise Performance and Fatigue Resistance  

Supplementation with *Gynostemma pentaphyllum* extract accelerates exercise-induced skeletal muscle AMPK Thr172 phosphorylation, increases mitochondrial oxygen flux, and elevates vascular eNOS to support oxygen delivery. Two independent double-blind RCTs led by Ahn et al. ([2023](https://pubmed.ncbi.nlm.nih.gov/36877124/), co-authored by manufacturer BTC Corporation) in 100 healthy Korean adults over 12 weeks and by Nayyar et al. ([2023](https://pubmed.ncbi.nlm.nih.gov/38004115/)) in 16 healthy untrained Australian males over 4 weeks demonstrated significant improvements in cardiorespiratory endurance, cycling time-trial speed, and perceived exertion without conflicting human trials.  

**Magnitude:** Over 12 weeks (N = 100), gypenoside L extract significantly increased VO₂ max (maximal oxygen uptake, a measure of aerobic fitness; p = 0.007), oxygen pulse (p = 0.047), and blood eNOS (p = 0.047) while lowering perceived exertion and fatigue scores (p < 0.05) versus placebo ([Ahn et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36877124/)), and 450 mg/day for 4 weeks significantly improved 20-km cycling time-trial performance versus placebo ([Nayyar et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38004115/)).  

#### Lipid Profile Modulation ⚠️ Conflicted  

Gypenosides suppress hepatic SREBP-1c lipogenesis and activate FXR bile-acid excretion. Meta-analyses by Dai et al. ([2022](https://pubmed.ncbi.nlm.nih.gov/36091752/), 22 RCTs) and Li et al. ([2023](https://pubmed.ncbi.nlm.nih.gov/37129524/)) plus an RCT by Rao et al. ([2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)) showed triglyceride reductions and HDL-C increases, whereas Dai et al. ([2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)) found monotherapy inferior to red yeast rice, Park et al. ([2014](https://pubmed.ncbi.nlm.nih.gov/23804546/)) and Huyen et al. ([2010](https://pubmed.ncbi.nlm.nih.gov/20213586/)) found unchanged lipids, and Jeenduang et al. ([2017](https://pubmed.ncbi.nlm.nih.gov/28244718/)) noted genotype-specific HDL-C decreases. Jiaogulan lowers triglycerides as an add-on in dyslipidemia but yields inconsistent monotherapy lipid effects.  

**Magnitude:** Added to lipid-lowering drugs in dyslipidemia, Jiaogulan reduced triglycerides by MD -0.65 mmol/L (95% CI -1.03 to -0.28) and LDL-C (low-density lipoprotein cholesterol, atherogenic cholesterol particles) by MD -0.57 mmol/L (95% CI -1.07 to -0.08) and raised HDL-C by MD +0.15 mmol/L (95% CI 0.11 to 0.20), but was inferior to red yeast rice for total cholesterol by MD +0.64 mmol/L (95% CI 0.15 to 1.13) ([Dai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)).  

#### Hepatic Steatosis and Liver Enzyme Modulation ⚠️ Conflicted  

By suppressing hepatic lipogenesis and TNF-α (tumor necrosis factor-alpha, a pro-inflammatory cytokine), *Gynostemma pentaphyllum* reduces liver stress in steatosis (fatty liver accumulation). Independent RCTs by Chou et al. ([2006](https://pubmed.ncbi.nlm.nih.gov/16708768/), reviewed by [Liu et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23975682/)) in NAFLD (nonalcoholic fatty liver disease) and Rao et al. ([2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)) lowered AST (aspartate aminotransferase), ALP (alkaline phosphatase), uric acid, ALT (alanine aminotransferase, liver enzymes), and TNF-α, whereas ultrasound steatosis ([Chou et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16708768/)) and enzymes in non-steatotic adults ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/)) were unchanged. Evidence supports modest enzyme reductions without imaging reversal.  

**Magnitude:** In overweight adults over 16 weeks (N = 117), 450 mg/day extract produced statistically significant between-group reductions in plasma ALT and TNF-α compared with placebo ([Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)), and in NAFLD patients over 4 months of add-on therapy (N = 56), it significantly reduced AST, ALP, and serum uric acid (p = 0.028) versus diet plus placebo ([Chou et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16708768/)).  

### Medium 🟩 🟩  

#### Anxiety Reduction Under Chronic Psychological Stress ⚠️ Conflicted  

Gypenosides modulate central GABAergic (gamma-aminobutyric acid-mediated, the brain's primary calming neurotransmitter system) signaling and stress-induced neuroinflammation. In an 8-week double-blind RCT of 72 chronically stressed adults, Choi et al. ([2019](https://pubmed.ncbi.nlm.nih.gov/30599899/)) showed that 400 mg/day of *Gynostemma pentaphyllum* leaf extract significantly reduced trait anxiety scores versus placebo, whereas total anxiety scores showed only a trend and a systematic review by Lopresti et al. ([2022](https://pubmed.ncbi.nlm.nih.gov/33650944/)) found inconclusive effects on HPA-axis hormone levels. Evidence supports modest trait-anxiety reduction under chronic stress without confirmed cortisol lowering.  

**Magnitude:** Over 8 weeks (N = 72), 400 mg/day leaf extract reduced the Trait Anxiety Scale score of the State-Trait Anxiety Inventory by 16.8% compared with placebo (p = 0.041), while total State-Trait Anxiety Inventory scores decreased by 17.8% within the active group without reaching statistical significance between groups ([Choi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30599899/)).  

#### Hair Density, Diameter, and Elasticity Enhancement ⚠️ Conflicted ⭕️ Not Central to Health & Longevity  

Bearing on cosmetic hair quality rather than longevity, *Gynostemma pentaphyllum* saponins stimulate dermal papilla proliferation. In a 24-week double-blind RCT of 100 adults with damaged hair led by Lee et al. ([2025](https://pubmed.ncbi.nlm.nih.gov/40077637/), co-authored by developer Easy Hydrogen Corporation), 340 mL/day of extract beverage significantly increased hair density, shaft diameter, and elasticity versus placebo, but did not alter hair glossiness (p > 0.05) or expert-assessed frontal and vertex hair-loss patterns. Supplementation improves hair shaft thickness and density in damaged hair without reversing clinical pattern baldness.  

**Magnitude:** Over 24 weeks (N = 100), daily *Gynostemma pentaphyllum* extract increased hair density by approximately 9 hairs/cm² (a threefold greater increase than placebo), hair diameter by approximately 14 µm (a fourfold greater increase than placebo), and hair elasticity threefold over placebo, whereas hair glossiness did not significantly differ (p > 0.05) ([Lee et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40077637/)).  

### Low 🟩  

#### Coronary Microvascular Endothelial and Inflammatory Biomarker Improvement  

In an RCT of 78 coronary artery disease patients by Dong et al. ([2023](https://pubmed.ncbi.nlm.nih.gov/37782173/)), 2 months of *Gelanxinning* capsules improved vascular SIRT1, adropin, NLRP3, interleukin-1, syndecan-1, and endocan. Because gypenosides were tested only alongside *Pueraria lobata* and hawthorn extract, this evidence is indirect for isolated Jiaogulan.  

**Magnitude:** Compared with control (N = 78), 2 months of the gypenoside combination increased serum SIRT1 (5.63 ± 0.30 vs. 4.22 ± 0.37, p < 0.01) and adropin (7.75 ± 0.59 vs. 5.71 ± 0.68, p = 0.03) and reduced NLRP3 (0.71 ± 0.08 vs. 1.04 ± 0.07, p < 0.01) and endocan (0.09 ± 0.01 vs. 0.19 ± 0.03, p < 0.01) ([Dong et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37782173/)).  

#### Retinal Ganglion Layer Preservation in Acute Optic Neuritis ⚠️ Conflicted ⭕️ Not Central to Health & Longevity  

Bearing on acute ophthalmic injury rather than longevity, Lu et al. ([2026](https://pubmed.ncbi.nlm.nih.gov/42398278/)) tested 180 mg/day gypenosides plus corticosteroids in a terminated pilot RCT (N = 10). Primary retinal nerve fiber thickness and macular volume were null, whereas exploratory ganglion layer thickness differed nominally without functional benefit.  

**Magnitude:** At 6 months (N = 9 analyzed), between-group differences were non-significant for primary peripapillary retinal nerve fiber layer thickness (+16.2 µm, 95% CI -16.3 to 48.6; p = 0.274) and macular volume (+0.034 mm³, 95% CI -0.166 to 0.234; p = 0.696), with +18.0 µm (95% CI 7.8 to 28.3; nominal p = 0.004) on exploratory ganglion layer thickness ([Lu et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42398278/)).  

### Speculative 🟨  

#### Lifespan Extension and Cellular Senescence Delay  

In *Caenorhabditis elegans* and rodent aging models, gypenosides and polysaccharides extend lifespan and reduce oxidative DNA damage via AMPK/SIRT1/FOXO1 signaling. No controlled human longevity studies exist, making this evidence preclinical only.  

#### Antitumor Proliferation Inhibition and Apoptosis Induction  

In cancer cell lines and mouse xenografts, gypenosides inhibit PI3K/AKT (phosphoinositide 3-kinase/protein kinase B, a cell-survival pathway) signaling and trigger tumor apoptosis. Controlled human oncology trials of isolated Jiaogulan are lacking.  

#### Dopaminergic Neuroprotection and Cognitive Preservation  

In rodent and cellular models of Parkinson's and Alzheimer's disease, *Gynostemma pentaphyllum* extracts attenuate neurotoxin-induced dopaminergic neuronal death and neuroinflammation. No controlled human neurodegenerative trials have evaluated these outcomes.  

  
## Benefit-Modifying Factors  

* **Genetic polymorphisms:** In hypercholesterolemic adults ([Jeenduang et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28244718/)), CETP (cholesteryl ester transfer protein, a lipid-transfer protein) TaqIB B2 carriers achieved significant total cholesterol and fasting glucose reductions from Jiaogulan tea, whereas APOE (apolipoprotein E, a cholesterol-transport gene) E4 carriers showed blunted glycemic responses.  
* **Baseline biomarker levels:** Glycemic and lipid improvements are largest in individuals with elevated baseline fasting glucose (>7.0 mmol/L), HbA1c (>7.0%), or hypertriglyceridemia ([Wang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42064816/)), whereas normoglycemic and normolipidemic adults experience minimal shifts ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/)).  
* **Sex-based differences:** In a 16-week DEXA (dual-energy X-ray absorptiometry, a precision body-composition scan) trial of 450 mg/day *Gynostemma pentaphyllum* extract ([Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)), overweight males achieved statistically significant reductions in visceral fat, whereas females primarily lost gynoid (hip and thigh) fat.  
* **Pre-existing health conditions:** Patients with type 2 diabetes, metabolic syndrome, or NAFLD show pronounced improvements in insulin sensitivity, transaminases, and triglycerides ([Huyen et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20213586/); [Chou et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16708768/)), whereas healthy lean adults primarily gain exercise and mitochondrial benefits ([Nayyar et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38004115/)).  
* **Age-related considerations:** Because endogenous cellular AMPK activity and mitochondrial biogenesis decline with age, middle-aged and older adults with metabolic inflexibility may experience greater relative AMPK restoration than young trained adults, though direct age-stratified clinical trials are lacking.  

  
## Potential Risks & Side Effects  

<!-- A dedicated search for the complete side effect, toxicity, and adverse event profile of Jiaogulan (Gynostemma pentaphyllum) and gypenosides was conducted across PubMed, ClinicalTrials.gov, Examine.com, and ConsumerLab.com before writing this section. The search specifically covered both reports of harm (such as reversible thrombocytopenia/leukopenia in Ding et al. 2025, mild within-range hematological shifts in Park et al. 2014, and genotype-specific HDL-C decreases in Jeenduang et al. 2017) and randomized trials and systematic reviews finding no excess risk or lower adverse event rates compared to control or comparator drugs (Dai et al. 2022, Rao et al. 2022, Huyen et al. 2010, Choi et al. 2019, and Lee et al. 2025). -->  

### High 🟥 🟥 🟥  

No risk reaches High: randomized controlled trials from multiple independent research groups have found no statistically significant excess of clinical adverse events or laboratory toxicities compared with placebo.  

### Medium 🟥 🟥  

No risk reaches Medium: no single randomized controlled trial or controlled observational cohort has demonstrated a statistically significant increase in any adverse clinical endpoint or validated safety surrogate over control.  

### Low 🟥  

#### Thrombocytopenia, Leukopenia, and Mild Hematological Shifts ⚠️ Conflicted  

A case report ([Ding et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40779472/)) documented reversible thrombocytopenia (low platelet count) and leukopenia (low white blood cell count), and Park et al. ([2014](https://pubmed.ncbi.nlm.nih.gov/23804546/)) noted minor count shifts, whereas RCTs ([Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)) found no toxicity. Routine use preserves normal blood counts despite rare cytopenias.  

**Magnitude:** In 1 case report (no control group), platelets fell to 6.0 × 10⁹/L and leukocytes to 3.27 × 10⁹/L before rebounding to 156 × 10⁹/L and 5.52 × 10⁹/L after discontinuation ([Ding et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40779472/)), whereas hematological adverse-event rates were 0% in both active and placebo groups across RCTs ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/); [Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)).  

#### Mild Gastrointestinal Discomfort ⚠️ Conflicted  

Saponin extracts occasionally cause nausea or diarrhea in dyslipidemia trials ([Dai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)). However, Dai et al. ([2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)) found fewer adverse events than lipid drugs, and RCTs ([Huyen et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20213586/); [Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)) reported zero gastrointestinal events. Digestive upset is rare and matches placebo rates.  

**Magnitude:** Across placebo-controlled trials of 400–450 mg/day extract or 6 g/day leaf tea, treatment-related gastrointestinal adverse-event rates were 0% in both *Gynostemma pentaphyllum* and placebo groups ([Huyen et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20213586/); [Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/); [Choi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30599899/); [Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)), with lower overall adverse events than comparator lipid drugs across 22 RCTs ([Dai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)).  

#### Genotype-Specific HDL Cholesterol Reduction ⚠️ Conflicted  

In an uncontrolled 30-day study, Jeenduang et al. ([2017](https://pubmed.ncbi.nlm.nih.gov/28244718/)) observed within-group HDL-C reductions in non-APOE4 and CETP B2 carriers drinking Jiaogulan tea. Conversely, RCT meta-analyses ([Dai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36091752/); [Li et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37129524/)) showed significant HDL-C increases. Controlled evidence indicates Jiaogulan generally raises or preserves HDL-C.  

**Magnitude:** In an uncontrolled 30-day tea arm (no control group for placebo comparison), HDL-C decreased significantly in non-APOE4 carriers (p = 0.009) and CETP B2 carriers (p = 0.004) ([Jeenduang et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28244718/)), whereas controlled trials showed an add-on HDL-C increase of MD +0.15 mmol/L (95% CI 0.11 to 0.20) ([Dai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)).  

### Speculative 🟨  

#### Platelet Aggregation Inhibition and Bleeding Tendency  

In vitro exposure of human blood to aqueous *Gynostemma pentaphyllum* extract inhibits platelet aggregation and prolongs coagulation times ([Tan et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8219678/)). No clinical bleeding events have been reported in controlled human trials.  

#### Additive Hypoglycemia with Antidiabetic Medications  

Damulins and phanoside stimulate AMPK glucose disposal and insulin secretion, creating a theoretical hypoglycemia risk alongside antidiabetic drugs. However, an 8-week gliclazide add-on RCT recorded zero hypoglycemic episodes ([Huyen et al., 2012](https://pubmed.ncbi.nlm.nih.gov/23125867/)).  

#### Immune Stimulation in Autoimmune Conditions  

Preclinical models show *Gynostemma pentaphyllum* polysaccharides and gypenosides activate macrophages, T-lymphocytes, and natural killer cells ([Su et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34684830/)). This raises a theoretical risk of flaring autoimmune disease or opposing immunosuppression.  

  
## Risk-Modifying Factors  

* **Genetic polymorphisms:** Slow metabolizers of CYP2D6 or UGT1A4 may experience stronger enzyme inhibition with gypenosides ([He et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23583485/); [Chen et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36674970/)), while non-APOE4 and CETP B2 carriers showed HDL-C reductions with tea ([Jeenduang et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28244718/)).  
* **Baseline biomarker levels:** Individuals with borderline-low platelet counts (<150 × 10⁹/L), leukopenia, or borderline anemia face higher risk if mild hematological shifts or idiosyncratic thrombocytopenia occur ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/); [Ding et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40779472/)).  
* **Sex-based differences:** Premenopausal females with lower baseline ferritin and hemoglobin stores are more susceptible to crossing anemia thresholds if mild within-range reductions in red blood cell indices occur during prolonged use ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/)).  
* **Pre-existing health conditions:** Patients with coagulopathies (clotting disorders), thrombocytopenia, active peptic ulcers, or recent cerebral infarction require caution due to in-vitro antiplatelet activity and a reported post-stroke thrombocytopenia case ([Tan et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8219678/); [Ding et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40779472/)).  
* **Age-related considerations:** Older adults frequently use concurrent anticoagulants, antiplatelets, or CYP2D6- and CYP3A4-metabolized cardiovascular and antidiabetic drugs, increasing susceptibility to pharmacokinetic and pharmacodynamic herb-drug interactions ([He et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23583485/)).  

  
## Key Interactions & Contraindications  

<!-- A dedicated search for published human interaction and pharmacokinetic studies of Jiaogulan (Gynostemma pentaphyllum) and gypenosides was performed across PubMed using terms including "drug interaction", "pharmacokinetics", "CYP", "cytochrome P450", "UGT", and "platelet" before writing this section. Identified studies include the human clinical add-on trial with gliclazide (Huyen et al., 2012, PMID 23125867), human liver microsome CYP450 inhibition (He et al., 2013, PMID 23583485) and UGT1A4 glucuronidation (Chen et al., 2023, PMID 36674970), in-vitro human platelet/coagulation inhibition (Tan et al., 1993, PMID 8219678), and a retrospective chart review of adaptogen-antidepressant interactions (Siwek et al., 2023, PMID 37829299). -->  

* **Sulfonylureas (insulin-releasing diabetes drugs) and antidiabetics (gliclazide, glimepiride, metformin, insulin):** Monitor. Adding 6 g/day extract to gliclazide (30 mg/day) lowered HbA1c by 2.0% without hypoglycemia ([Huyen et al., 2012](https://pubmed.ncbi.nlm.nih.gov/23125867/)), but additive glucose lowering warrants glucose monitoring and potential dose adjustment.  
* **CYP2D6-metabolized medications (metoprolol, carvedilol, fluoxetine, paroxetine, tamoxifen):** Caution (theoretical). Gypenosides competitively inhibit human CYP2D6 in vitro with an IC50 (half-maximal inhibitory concentration) of 1.61 µg/mL ([He et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23583485/)), potentially elevating plasma drug levels; separate dosing by 3–4 hours and monitor clinical effects.  
* **CYP2C8, CYP3A4, CYP2C9, and UGT1A4 substrates (atorvastatin, midazolam, losartan, warfarin, lamotrigine):** Monitor (theoretical). Gypenosides moderately inhibit human CYP2C8, CYP3A4, and CYP2C9 in vitro ([He et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23583485/)) and utilize UGT1A4 ([Chen et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36674970/)), potentially slowing clearance of narrow-index substrates.  
* **Anticoagulant and antiplatelet prescription medications (warfarin, apixaban, rivaroxaban, clopidogrel):** Caution (theoretical). Aqueous extract inhibits human platelet aggregation and prolongs coagulation times in vitro ([Tan et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8219678/)) and rarely causes thrombocytopenia ([Ding et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40779472/)), increasing bleeding risk; monitor platelets and coagulation.  
* **Immunosuppressive medications (cyclosporine, tacrolimus, azathioprine, mycophenolate, prednisone):** Avoid (theoretical). Preclinical data show *Gynostemma pentaphyllum* polysaccharides and gypenosides stimulate T-lymphocyte, macrophage, and natural killer cell activity ([Su et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34684830/)), which could antagonize pharmacological immunosuppression in transplant or autoimmune patients.  
* **Over-the-counter nonsteroidal anti-inflammatory drugs and salicylates (aspirin, ibuprofen, naproxen):** Monitor (theoretical). Concurrent use with over-the-counter antiplatelet or mucosal-irritating analgesics may compound theoretical antiplatelet effects ([Tan et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8219678/)) and upper gastrointestinal irritation; administer with food and monitor for bruising.  
* **AMPK-activating and hypoglycemic supplements (berberine, alpha-lipoic acid, *Gymnema sylvestre*, chromium):** Monitor (theoretical). Co-administration produces additive AMPK activation and glucose disposal, increasing the likelihood of low fasting blood glucose when stacked; stagger initiation and track fasting glucose.  
* **Antiplatelet and fibrinolytic supplements (*Ginkgo biloba*, nattokinase, omega-3 fatty acids, garlic extract):** Monitor (theoretical). Combining with antiplatelet supplements may compound in-vitro platelet inhibition ([Tan et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8219678/)), although trials combining Jiaogulan with omega-3 fatty acids reported no bleeding ([Dai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)).  
* **Prolonged multi-day fasting protocols:** Monitor (theoretical). Because fasting and damulin-standardized *Gynostemma pentaphyllum* both activate cellular AMPK and suppress hepatic gluconeogenesis ([Yassin et al., 2011](https://pubmed.ncbi.nlm.nih.gov/23675229/)), taking concentrated extracts during extended water fasts may exaggerate blood glucose reductions; administer with meals.  

**Populations who should avoid Jiaogulan:**  

* Individuals with baseline thrombocytopenia (platelet count $<150 \times 10^9/\text{L}$) or history of drug-induced cytopenia, given a documented case of severe reversible thrombocytopenia ($6.0 \times 10^9/\text{L}$) and leukopenia ($3.27 \times 10^9/\text{L}$) after three months of use ([Ding et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40779472/)).  
* Pregnant or breastfeeding women, who were systematically excluded from human clinical trials ([NCT01667224](https://clinicaltrials.gov/study/NCT01667224); [Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/)) and due to historical teratogenic concerns with related triterpenoid saponin preparations.  
* Surgical patients within 14 days prior to scheduled invasive procedures, due to in-vitro inhibition of platelet aggregation, prolongation of prothrombin and thrombin times ([Tan et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8219678/)), and potential glycemic fluctuations.  
* Patients with decompensated cardiovascular disease (arrhythmia, heart failure, myocardial infarction, or pacemaker), acute or chronic renal failure, abnormal hepatic function, or prior gastrointestinal surgery, all excluded from pivotal clinical trials ([NCT01667224](https://clinicaltrials.gov/study/NCT01667224)).  
* Individuals with active autoimmune disorders or organ transplants receiving immunosuppressive therapy, due to immunostimulatory effects of *Gynostemma* polysaccharides and saponins ([Su et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34684830/)).  

  
## Risk Mitigation Strategies  

Doses and timings below follow common practice unless cited.  

* **Complete blood count monitoring:** Check blood counts at baseline, 4 weeks, and 12 weeks, stopping immediately if platelets fall below $150 \times 10^9/\text{L}$ or leukocytes below $4.0 \times 10^9/\text{L}$ to prevent severe thrombocytopenia or leukopenia ([Ding et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40779472/)).  
* **Divided meal-timed dosing:** Administer 200–225 mg of standardized extract twice daily with or 30 minutes before breakfast and dinner ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/); [Choi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30599899/)) to mitigate saponin-induced gastric irritation, nausea, and fasted glucose dips.  
* **Perioperative washout window:** Discontinue all *Gynostemma pentaphyllum* teas and extracts at least 14 days before elective surgery or dental extractions to prevent excessive perioperative bleeding from platelet aggregation inhibition and coagulation prolongation ([Tan et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8219678/)).  
* **CYP2D6 and anticoagulant spacing:** Separate administration by 3–4 hours from CYP2D6-metabolized medications ([He et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23583485/)) and avoid unmonitored combination with prescription anticoagulants to reduce pharmacokinetic accumulation and bleeding risk.  
* **Lipid subfraction verification:** Re-check HDL-C at 4–12 weeks in individuals with hypercholesterolemia or known CETP TaqIB B2 / non-APOE4 genotypes, discontinuing if HDL-C declines >10% from baseline to avoid unintended HDL-C reduction ([Jeenduang et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28244718/)).  

  
## Therapeutic Protocol  

Parameters below without a citation (such as titration steps, timing relative to workouts, and cycling schedules) reflect common practice.  

* **Standard AMPK and body-composition extract regimen:** 450 mg/day of heat-processed extract standardized to damulins A (≥1.1–2.49%) and B (≥1.06%), taken orally as 225 mg twice daily or 450 mg once daily ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/); [Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)).  
* **Chronic stress and anxiety extract regimen:** 400 mg/day of aqueous-ethanol *Gynostemma pentaphyllum* leaf extract administered orally as 200 mg twice daily for 8 weeks, as established by Chonbuk National University Hospital researchers ([Choi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30599899/)).  
* **Traditional glycemic leaf-tea regimen:** 6 g/day of authenticated dried whole leaves (~18% gypenosides) infused in warm water as 3 g twice daily, established by Karolinska Institute and Hanoi Medical University trials ([Huyen et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20213586/); [Huyen et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23431428/)).  
* **Practitioner and longevity formulation approach:** Integrative longevity protocols (such as Life Extension's AMPK Metabolic Activator; [Robert Friedman, 2026](https://www.lifeextension.com/magazine/2026/1/activate-ampk-and-metabolic-health)) pair 450 mg/day of ActivAMP *Gynostemma pentaphyllum* extract with 500 mg/day hesperidin to combine metabolic AMPK and vascular endothelial benefits.  
* **Optimal time of day:** Administer 30 minutes before breakfast and dinner for glycemic and body-composition goals ([Huyen et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23431428/)), or 60 minutes before endurance training when targeting muscle AMPK phosphorylation and cycling performance ([Nayyar et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38004115/)).  
* **Expected half-life:** Human elimination half-life is unestablished; in rats, gypenoside XVII shows rapid absorption with a Tmax (time to peak plasma concentration) of 0.17–0.20 hours, a 1.94–2.56 hour elimination half-life, and 1.87% oral bioavailability ([Wang et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28959853/)).  
* **Single versus split dosing:** Twice-daily dosing (200–225 mg extract or 3 g tea) is favored in metabolic trials ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/)) to offset rapid clearance, though 450 mg once daily also works ([Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)).  
* **Genetic polymorphism considerations:** CETP TaqIB B2 and non-APOE4 carriers achieve stronger glucose and cholesterol reductions from tea but require HDL-C tracking ([Jeenduang et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28244718/)), while CYP2D6 poor metabolizers should avoid narrow-index CYP2D6 substrates ([He et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23583485/)).  
* **Sex-based dosing and response:** Both sexes use the same 450 mg/day extract dose without adjustment, but body-composition responses diverge: men predominantly lose visceral intra-abdominal fat whereas women predominantly lose gynoid hip and thigh fat ([Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)).  
* **Age-related protocol adjustments:** Adults up to age 70 tolerate 400–450 mg/day extract or 6 g/day tea in trials ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/); [Huyen et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20213586/)); older adults on polypharmacy commonly start at 225 mg/day for 1–2 weeks.  
* **Baseline biomarker stratification:** Adults with elevated HbA1c or insulin resistance respond to 6 g/day tea or 450 mg/day extract ([Wang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42064816/)), whereas overweight normoglycemic adults targeting visceral fat require heat-processed damulin extract ([Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)).  
* **Pre-existing health condition modifications:** In type 2 diabetes treated with sulfonylureas, adding 6 g/day extract requires home glucose monitoring ([Huyen et al., 2012](https://pubmed.ncbi.nlm.nih.gov/23125867/)); in dyslipidemia, combining with omega-3 fatty acids or statins outperforms monotherapy ([Dai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)).  

  
## Discontinuation & Cycling  

* **Short-term versus continuous longevity use:** Controlled human trials have evaluated continuous daily supplementation for 4 to 24 weeks ([Nayyar et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38004115/); [Lee et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40077637/)); while traditional tea is consumed long-term, multi-year extract safety lacks trial data.  
* **Withdrawal effects and effect reversal:** Abrupt cessation causes no withdrawal syndrome or rebound effects; however, in a 4-week crossover RCT, fasting glucose and insulin sensitivity returned toward baseline within 2–4 weeks of stopping leaf tea ([Huyen et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23431428/)).  
* **Tapering-off protocol:** Because *Gynostemma pentaphyllum* does not suppress endogenous endocrine axes or induce receptor dependence, no tapering schedule is required when discontinuing standalone use, though diabetic patients on concurrent hypoglycemic medications should monitor glucose during cessation.  
* **Cycling for efficacy and hematological safety:** To mitigate adaptogenic desensitization and rare hematological shifts observed after 3 months of continuous use ([Ding et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40779472/)), longevity protocols commonly employ 12–16 week active cycles followed by a 2–4 week washout.  

  
## Sourcing and Quality  

* **Extract standardization and heat processing:** Raw *Gynostemma pentaphyllum* leaves contain minimal damulins A and B; autoclave heat-processing converts precursor saponins into AMPK-activating damulins (≥1.1–2.49% damulin A and ≥1.06% damulin B in Actiponin/ActivAMP; [NCT01667224](https://clinicaltrials.gov/study/NCT01667224)), whereas generic extracts standardize only total gypenosides (80–98%).  
* **Botanical authentication and adulteration prevention:** Wild-harvested Jiaogulan is occasionally adulterated with *Causonis japonica* (*Cayratia japonica*, bushkiller vine), which lacks dammarane gypenosides; verify HPLC (high-performance liquid chromatography, an analytical compound-verification method) testing for gypenoside XLIX, Rb1, or damulins A/B.  
* **Third-party contaminant screening:** Cultivated in southern China and northern Vietnam, *Gynostemma pentaphyllum* bioaccumulates soil heavy metals (lead, cadmium, arsenic) and pesticides; select products with independent ISO-17025 (International Organization for Standardization laboratory standard) or USP (United States Pharmacopeia) heavy-metal certificates.  
* **Validated commercial ingredients and brands:** Clinical body-composition and exercise trials used Gencor Pacific's ActivAMP / TG Biotech's Actiponin ([Park et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23804546/); [Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)), available in third-party tested formulas from Life Extension (AMPK Metabolic Activator) and Swanson, plus organic teas from Immortalitea.  

  
## Practical Considerations  

* **Time to effect:** Improvements in muscle AMPK phosphorylation, fasting glucose, and cycling performance emerge within 4 weeks ([Huyen et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23431428/); [Nayyar et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38004115/)), anxiety reduction within 8 weeks ([Choi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30599899/)), and fat loss over 12–16 weeks ([Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)).  
* **Common pitfalls:** Substituting unstandardized raw leaf powder or sweet-variant tea for heat-processed damulin-standardized extract when targeting visceral fat loss, or relying on Jiaogulan monotherapy instead of red yeast rice or statins for primary LDL-C reduction ([Dai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)).  
* **Regulatory status:** Marketed in the United States and Australia as an over-the-counter dietary supplement ([Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/); [Huang et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35282005/)) and classified in China as a "medicine food homology" functional food and lipid-lowering phytomedicine ([Wang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42064816/); [He et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23583485/)).  
* **Cost and accessibility:** Both whole-leaf teas and standardized ActivAMP/Actiponin capsules are inexpensive ($12–$30 US dollars per month) and widely accessible online without a prescription across North America, Asia, and Australia.  

  
## Interaction with Foundational Habits  

* **Sleep:** Indirect potentiating interaction. Unlike *Panax ginseng*, *Gynostemma pentaphyllum* is non-stimulating and reduces chronic stress-related trait anxiety ([Choi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30599899/)), which may indirectly support sleep onset in anxious individuals; however, avoid taking large tea volumes immediately before bed to prevent nocturia (nighttime urination).  
* **Nutrition:** Direct potentiating interaction. High-carbohydrate or hypercaloric meals suppress endogenous cellular AMPK, whereas pairing *Gynostemma pentaphyllum* with caloric moderation, dietary soluble fiber, or omega-3 fatty acids potentiates triglyceride normalization ([Dai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)) and hepatic fat reduction ([Chou et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16708768/)); take 30 minutes pre-meal.  
* **Exercise:** Direct potentiating interaction. Unlike metformin, which can blunt aerobic adaptations, 450 mg/day *Gynostemma pentaphyllum* extract accelerates post-exercise skeletal muscle AMPK Thr172 phosphorylation, increases mitochondrial oxygen flux, improves 20-km cycling performance ([Nayyar et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38004115/)), and raises VO₂ max and eNOS ([Ahn et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36877124/)).  
* **Stress management:** Direct potentiating interaction. Ethanol leaf extract (400 mg/day) attenuates chronic psychological stress-induced trait anxiety by 16.8% ([Choi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30599899/)) through central GABAergic and monoaminergic modulation, complementing mindfulness or breathwork practices even though resting cortisol levels remain largely unchanged ([Lopresti et al., 2022](https://pubmed.ncbi.nlm.nih.gov/33650944/)).  

  
## Monitoring Protocol & Defining Success  

Before initiating *Gynostemma pentaphyllum*, baseline laboratory testing establishes personalized metabolic benchmarks and rules out hematological or hepatic contraindications. Comprehensive baseline assessment includes fasting plasma glucose, fasting serum insulin (to calculate HOMA-IR), HbA1c, a standard lipid panel (triglycerides, HDL-C, LDL-C), a complete blood count with differential and platelets, and hepatic transaminases (ALT, AST, ALP), alongside a baseline DEXA body-composition scan when targeting visceral or gynoid adiposity. Ongoing clinical monitoring is performed at 4 weeks (to verify early fasting glucose response, HDL-C stability, and platelet counts), at 12–16 weeks (to evaluate HbA1c, triglycerides, liver enzymes, and repeat DEXA fat mass), and every 6 months during continued use.  

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| :--- | :--- | :--- | :--- |
| Fasting Plasma Glucose | 3.9–5.5 mmol/L (70–99 mg/dL) (standard reference range) | Efficacy marker (expected to decrease in insulin resistance) and safety check for hypoglycemia. | Collect after an 8–12 hour overnight fast; meta-analysis shows MD -0.79 mmol/L ([Wang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42064816/)). |
| HbA1c | <5.7% (standard reference range) | Efficacy marker (expected to decrease over 8–12 weeks in elevated states). | HbA1c (glycated hemoglobin); reflects 90-day glycemia; meta-analysis shows MD -1.01% ([Wang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42064816/)). |
| Serum Triglycerides | <1.7 mmol/L (<150 mg/dL) (standard reference range) | Efficacy marker (expected to decrease via AMPK and FXR hepatic lipid oxidation). | Fasting 12-hour draw; reduced by MD -0.65 mmol/L as add-on therapy ([Dai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36091752/)). |
| Serum HDL-C | >1.0 mmol/L men, >1.3 mmol/L women (standard reference range) | Efficacy marker (generally increases) and safety check in CETP B2 / non-APOE4 carriers. | HDL-C (high-density lipoprotein cholesterol); stop if HDL-C drops >10% ([Jeenduang et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28244718/)). |
| Platelet & Leukocyte Count (CBC) | Platelets 150–450 × 10⁹/L; WBC 4.5–11.0 × 10⁹/L (standard reference range) | Safety check (stops use if thrombocytopenia or leukopenia develops). | CBC (complete blood count), WBC (white blood cell count); discontinue if platelets <150 × 10⁹/L ([Ding et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40779472/)). |
| Liver Enzymes (ALT, AST, ALP) | ALT 7–56 U/L; AST 8–33 U/L; ALP 44–147 U/L (standard reference range) | Efficacy marker in fatty liver disease and baseline safety check. | ALT (alanine aminotransferase), AST (aspartate aminotransferase), ALP (alkaline phosphatase); lowered in NAFLD ([Chou et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16708768/)). |
| Visceral & Total Fat Mass (DEXA) | No established target; track reduction from individual baseline | Efficacy marker (expected to decrease over 12–16 weeks with damulin-standardized extract). | DEXA (dual-energy X-ray absorptiometry); visceral fat decreases primarily in men, gynoid fat in women ([Rao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34323337/)). |

* **Endurance and perceived exertion:** Track 20-km cycling splits and post-exercise fatigue over 4–12 weeks ([Nayyar et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38004115/)).  
* **Stress resilience:** Assess trait anxiety over 8 weeks ([Choi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30599899/)).  
* **Digestive and bruising tolerance:** Confirm absence of nausea or easy bruising.  

  
## Emerging Research  

* **Hepatitis B cirrhosis recompensation trial ([NCT07017426](https://clinicaltrials.gov/study/NCT07017426)):** Upcoming multicenter double-blind RCT (N = 432, estimated completion July 2027) testing 48 weeks of *Fuzheng Huayu* tablets (containing *Gynostemma pentaphyllum*) on cirrhosis re-decompensation. A positive result would support multi-herb antifibrotic utility; a null result would weaken clinical hepatic claims beyond biochemical enzyme reductions.  
* **Metabolic syndrome saponin-dose trial ([NCT05118698](https://clinicaltrials.gov/study/NCT05118698)):** Three-arm trial (N = 150) at Xi'an Jiaotong University comparing 12% versus 8% saponin *Gynostemma pentaphyllum* powder against spinach placebo over 3 months; its registered March 2023 completion date has passed with status unknown and no results posted.  
* **North American overweight ActivAMP trial ([NCT02188251](https://clinicaltrials.gov/study/NCT02188251)):** Completed Phase 2 triple-blind RCT (N = 100, completed April 2015, no results posted) by KGK Science and Gencor Pacific evaluating 450 mg/day ActivAMP for 12 weeks; unpublished status leaves a potential publication-bias gap that could temper body-composition effect sizes.  
* **Terminated acute optic neuritis pilot trial ([NCT02976766](https://clinicaltrials.gov/study/NCT02976766)):** Phase 2 RCT of adjunctive gypenosides (180 mg/day for 10 days) terminated after 10 randomizations; published results ([Lu et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42398278/)) showed null primary retinal nerve fiber preservation (+16.2 µm, p = 0.274), weakening human neuroprotective translation.  
* **Adipose browning and skin senescence pathways:** Preclinical 2026 studies demonstrate that gypenosides induce white-adipocyte browning by inhibiting autophagy via the FXR/Rubicon pathway ([Wang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42663912/)) and that *Gynostemma pentaphyllum* extracellular vesicles attenuate skin aging by destabilizing STING (stimulator of interferon genes, an innate immune sensor; [Wang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41937947/)).  
* **Human CYP2D6 and UGT1A4 interaction validation:** In-vitro human liver microsome studies show competitive CYP2D6 inhibition ([He et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23583485/)) and UGT1A4 glucuronidation ([Chen et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36674970/)); future clinical pharmacokinetic trials in humans could either confirm clinically meaningful herb-drug interactions—weakening safety in polypharmacy—or show minimal systemic enzyme inhibition due to low oral bioavailability.  

  
## Conclusion  

Jiaogulan (*Gynostemma pentaphyllum*) is an East Asian climbing vine whose leaves supply dammarane-type plant compounds that activate the body's primary cellular energy-sensing enzyme, mimicking key metabolic and mitochondrial signaling pathways triggered by exercise and calorie restriction. For proactive, longevity-oriented adults, randomized human trials from multiple independent research groups support distinct applications depending on formulation: traditional whole-leaf tea infusions consistently lower fasting blood sugar, long-term blood sugar markers, and insulin resistance in individuals with elevated blood glucose, whereas heat-processed leaf extracts enriched in specific active compounds modestly reduce abdominal and hip fat mass and enhance aerobic exercise performance, muscle oxygen utilization, and fatigue resistance.  

Conversely, blood lipid and liver enzyme improvements are mainly seen when Jiaogulan is used as an add-on to existing lipid-lowering medications or diet rather than as a standalone replacement for red yeast rice or prescription cholesterol drugs. The evidence base is constrained by modest sample sizes, short study durations of one to six months, and direct manufacturer funding or co-authorship (by commercial extract developers including Gencor Pacific, TG Biotech, BTC Corporation, and Easy Hydrogen Corporation) across key body-composition, exercise, and hair trials. While short-term oral regimens show placebo-like tolerability, laboratory evidence of liver enzyme inhibition and platelet suppression, alongside a clinical report of severe reversible platelet and white blood cell depletion after three months of continuous use, highlights the importance of periodic blood count monitoring.  

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**  


